Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/04/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/04/2023 | 21.95% | Piper Sandler | $7 → $2 | Downgrades | Overweight → Neutral |
| 08/04/2023 | -8.54% | Chardan Capital | $2 → $1.5 | Maintains | Sell |
| 05/30/2023 | 21.95% | Chardan Capital | $2.5 → $2 | Maintains | Sell |
| 03/01/2023 | 52.44% | Chardan Capital | → $2.5 | Reiterates | → Sell |
| 02/01/2023 | 1302.44% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight |
| 12/06/2022 | — | Jefferies | Downgrades | Buy → Hold | |
| 09/06/2022 | 326.83% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 06/03/2022 | 52.44% | Chardan Capital | $6.5 → $2.5 | Maintains | Sell |
| 08/31/2021 | 296.34% | Chardan Capital | $7.5 → $6.5 | Maintains | Sell |
| 04/07/2021 | — | Maxim Group | Upgrades | Hold → Buy | |
| 01/19/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/04/2020 | 357.32% | Chardan Capital | $5.5 → $7.5 | Downgrades | Neutral → Sell |
| 11/20/2020 | 1119.51% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 10/22/2020 | 631.71% | RBC Capital | → $12 | Initiates Coverage On | → Sector Perform |
| 10/02/2020 | 1058.54% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/28/2020 | 1180.49% | HC Wainwright & Co. | $14 → $21 | Reiterates | → Buy |
| 10/22/2019 | 1302.44% | Cantor Fitzgerald | → $23 | Assumes | → Overweight |
| 01/31/2019 | 296.34% | HC Wainwright & Co. | → $6.5 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/07/2023 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 08/04/2023 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 08/04/2023 | 21.95% | 派珀·桑德勒 | 7 美元 → 2 美元 | 降級 | 超重 → 中性 |
| 08/04/2023 | -8.54% | 查丹資本 | $2 → 1.5 美元 | 維護 | 賣出 |
| 05/30/2023 | 21.95% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 賣出 |
| 03/01/2023 | 52.44% | 查丹資本 | → 2.5 美元 | 重申 | → 賣出 |
| 02/01/2023 | 1302.44% | 坎託·菲茨傑拉德 | → 23 美元 | 重申 | → 超重 |
| 12/06/2022 | — | 傑富瑞 | 降級 | 買入 → 持有 | |
| 09/06/2022 | 326.83% | 派珀·桑德勒 | → 7 美元 | 啓動覆蓋開啓 | → 超重 |
| 06/03/2022 | 52.44% | 查丹資本 | 6.5 美元 → 2.5 美元 | 維護 | 賣出 |
| 08/31/2021 | 296.34% | 查丹資本 | 7.5 美元 → 6.5 美元 | 維護 | 賣出 |
| 2021 年 7 月 4 日 | — | Maxim 集團 | 升級 | 持有 → 買入 | |
| 2021 年 1 月 19 日 | — | 傑富瑞 | 降級 | 買入 → 持有 | |
| 12/22/2020 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 2020 年 4 月 12 日 | 357.32% | 查丹資本 | 5.5 美元 → 7.5 美元 | 降級 | 中性 → 賣出 |
| 11/20/2020 | 1119.51% | HC Wainwright & Co. | 19 美元 → 20 美元 | 維護 | 購買 |
| 2020 年 10 月 22 日 | 631.71% | 加拿大皇家銀行資本 | → 12 美元 | 啓動覆蓋開啓 | → 行業表現 |
| 2020 年 2 月 10 日 | 1058.54% | HC Wainwright & Co. | 21 美元 → 19 美元 | 維護 | 購買 |
| 05/28/2020 | 1180.49% | HC Wainwright & Co. | 14 美元 → 21 美元 | 重申 | → 購買 |
| 2019 年 10 月 22 日 | 1302.44% | 坎託·菲茨傑拉德 | → 23 美元 | 假設 | → 超重 |
| 01/31/2019 | 296.34% | HC Wainwright & Co. | → 6.5 美元 | 假設 | → 購買 |
What is the target price for Mesoblast (MESO)?
Mesoblast (MESO) 的目標價格是多少？
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Maxim Group on August 7, 2023. The analyst firm set a price target for $0.00 expecting MESO to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
Maxim集團於2023年8月7日公佈了Mesoblast（納斯達克股票代碼：MESO）的最新目標股價。這家分析公司將目標股價定爲0.00美元，預計MESO將在12個月內降至-100.00％（可能下跌-100.00％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Mesoblast (MESO)?
分析師對Mesoblast（MESO）的最新評級是多少？
The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Maxim Group, and Mesoblast downgraded their hold rating.
Mesoblast（納斯達克股票代碼：MESO）的最新分析師評級由Maxim集團提供，Mesoblast下調了持倉評級。
When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?
Mesoblast（MESO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Mesoblast的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Mesoblast的最後一次評級是在2023年8月7日提交的，因此您應該預計下一個評級將在2024年8月7日左右公佈。
Is the Analyst Rating Mesoblast (MESO) correct?
分析師對 mesoblast (MESO) 的評級是否正確？
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Mesoblast (MESO) is trading at is $1.64, which is out of the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Mesoblast（MESO）評級被下調，目標股價爲0.00美元至0.00美元。Mesoblast（MESO）目前的交易價格爲1.64美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。